SMAD3 and neoplasm: IHC results indicated that siTGF-β1@ILP, modified with cetuximab, achieved active targeting, significantly enhanced the enrichment and gene silencing effects of siRNA in tumor cells, and exhibited strong inhibitory effects on TGF-β1 and p-Smad3 protein expression.